Cargando…
Levetiracetam Rectal Administration in Healthy Dogs
BACKGROUND: Levetiracetam is used to manage status epilepticus (SE) and cluster seizures (CS) in humans. The drug might be absorbed after rectal administration and could offer a practical adjunct to rectal administration of diazepam in managing SE and CS. HYPOTHESIS: Levetiracetam is rapidly absorbe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857990/ https://www.ncbi.nlm.nih.gov/pubmed/24417468 http://dx.doi.org/10.1111/jvim.12269 |
_version_ | 1782430727910981632 |
---|---|
author | Peters, R.K. Schubert, T. Clemmons, R. Vickroy, T. |
author_facet | Peters, R.K. Schubert, T. Clemmons, R. Vickroy, T. |
author_sort | Peters, R.K. |
collection | PubMed |
description | BACKGROUND: Levetiracetam is used to manage status epilepticus (SE) and cluster seizures (CS) in humans. The drug might be absorbed after rectal administration and could offer a practical adjunct to rectal administration of diazepam in managing SE and CS. HYPOTHESIS: Levetiracetam is rapidly absorbed after rectal administration in dogs and maintains target serum concentrations for at least 9 hours. ANIMALS: Six healthy privately owned dogs between 2 and 6 years of age and weighing 10–20 kg. METHODS: Levetiracetam (40 mg/kg) was administered rectally and blood samples were obtained immediately before (time zero) and at 10, 20, 40, 60, 90, 180, 360, and 540 minutes after drug administration. Dogs were observed for signs of adverse effects over a 24‐hour period after drug administration. RESULTS: C (LEV) at 10 minutes was 15.3 ± 5.5 μg/mL (mean, SD) with concentrations in the target range (5–40 μg/mL) for all dogs throughout the sampling period. C (max) (36.0 ± 10.7 μg/mL) and T (max) (103 ± 31 minutes) values were calculated and 2 disparate groups were appreciated. Dogs with feces in the rectum at the time of drug administration had lower mean C (max) values (26.7 ± 3.4 μg/mL) compared with those without (45.2 ± 4.4 μg/mL). Mild sedation was observed between 60 and 90 minutes without other adverse effects noted. CONCLUSIONS AND CLINICAL IMPORTANCE: This study supports the use of rectally administered levetiracetam in future studies of clinical effectiveness in the management of epileptic dogs. |
format | Online Article Text |
id | pubmed-4857990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48579902016-06-22 Levetiracetam Rectal Administration in Healthy Dogs Peters, R.K. Schubert, T. Clemmons, R. Vickroy, T. J Vet Intern Med Standard Articles BACKGROUND: Levetiracetam is used to manage status epilepticus (SE) and cluster seizures (CS) in humans. The drug might be absorbed after rectal administration and could offer a practical adjunct to rectal administration of diazepam in managing SE and CS. HYPOTHESIS: Levetiracetam is rapidly absorbed after rectal administration in dogs and maintains target serum concentrations for at least 9 hours. ANIMALS: Six healthy privately owned dogs between 2 and 6 years of age and weighing 10–20 kg. METHODS: Levetiracetam (40 mg/kg) was administered rectally and blood samples were obtained immediately before (time zero) and at 10, 20, 40, 60, 90, 180, 360, and 540 minutes after drug administration. Dogs were observed for signs of adverse effects over a 24‐hour period after drug administration. RESULTS: C (LEV) at 10 minutes was 15.3 ± 5.5 μg/mL (mean, SD) with concentrations in the target range (5–40 μg/mL) for all dogs throughout the sampling period. C (max) (36.0 ± 10.7 μg/mL) and T (max) (103 ± 31 minutes) values were calculated and 2 disparate groups were appreciated. Dogs with feces in the rectum at the time of drug administration had lower mean C (max) values (26.7 ± 3.4 μg/mL) compared with those without (45.2 ± 4.4 μg/mL). Mild sedation was observed between 60 and 90 minutes without other adverse effects noted. CONCLUSIONS AND CLINICAL IMPORTANCE: This study supports the use of rectally administered levetiracetam in future studies of clinical effectiveness in the management of epileptic dogs. John Wiley and Sons Inc. 2014-01-13 2014 /pmc/articles/PMC4857990/ /pubmed/24417468 http://dx.doi.org/10.1111/jvim.12269 Text en Copyright © 2014 by the American College of Veterinary Internal Medicine |
spellingShingle | Standard Articles Peters, R.K. Schubert, T. Clemmons, R. Vickroy, T. Levetiracetam Rectal Administration in Healthy Dogs |
title | Levetiracetam Rectal Administration in Healthy Dogs |
title_full | Levetiracetam Rectal Administration in Healthy Dogs |
title_fullStr | Levetiracetam Rectal Administration in Healthy Dogs |
title_full_unstemmed | Levetiracetam Rectal Administration in Healthy Dogs |
title_short | Levetiracetam Rectal Administration in Healthy Dogs |
title_sort | levetiracetam rectal administration in healthy dogs |
topic | Standard Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857990/ https://www.ncbi.nlm.nih.gov/pubmed/24417468 http://dx.doi.org/10.1111/jvim.12269 |
work_keys_str_mv | AT petersrk levetiracetamrectaladministrationinhealthydogs AT schubertt levetiracetamrectaladministrationinhealthydogs AT clemmonsr levetiracetamrectaladministrationinhealthydogs AT vickroyt levetiracetamrectaladministrationinhealthydogs |